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Abstract Current approaches to treat osteoarthritis (OA)
are insufficient. Autologous chondrocyte implantation
(ACI) has been used for the past decade to treat patients
with OA or focal cartilage defects. However, a number of
complications have been reported post-ACI, including
athrofibrosis and symptomatic hypertrophy. Thus, a
long-term ACI strategy should ideally incorporate
methods to ‘prime’ autologous chondrocytes to form a
cartilage-specific matrix and suppress hypertrophic miner-
alization. The objective of this study is to examine the
effects of tyrosine-rich amelogenin peptide (TRAP; an
isoform of the developmental protein amelogenin) on hu-
man articular cartilage cell (HAC) chondrogenic differen-
tiation and hypertrophic mineralization in vitro. Effects of
chemically synthesized TRAP on HAC chondrogenic dif-
ferentiation were determined by assessing: (1) sGAG pro-
duction; (2) Alcian blue staining for proteoglycans; (3)
collagen type II immunostaining; and (4) expression of
the chondrogenic genes SOX9, ACAN and COL2A1. Hy-
pertrophic mineralization was assayed by: (1) ALP ex-
pression; (2) Alizarin red staining for Ca+2-rich bone nod-
ules; (3) OC immunostaining; and (4) expression of the
osteogenic/hypertrophic genes Ihh and BSP. Chemically
synthesized TRAP was found to suppress terminal osteo-
genic differentiation of HACs cultured in hypertrophic
mineralization-like conditions, an effect mediated via
down-regulation of the Ihh gene. Moreover, TRAP was
found to augment chondrogenic differentiation of HACs
via induction of SOX9 gene expression when cells were
cultured in pro-chondrogenic media. The results obtained
from this proof-of-concept study motivate further studies
on the use of TRAP as part of a preconditioning regimen
in autologous chondrocyte implantation procedures for
OA patients and patients suffering from focal cartilage
defects.
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Introduction
Osteoarthritis (OA) is a joint disease characterized by progres-
sive degeneration of articular cartilage (Felson 2006). It was
recently identified as the second most common cause of dis-
ability and the major cause for disability allowance in the
United States (Felson 2006). OA is associated with the loss
of the proteoglycan-rich extracellular matrix (ECM) of carti-
lage and subsequent ECM mineralization (Felson 2006).
Physiotherapy, exercise and analgesics are currently used for
early stage management of OA, whereas in later stages, sur-
gical interventions are typically required (Bartha, et al. 2006;
Felson 2006). However, existing therapies do not reverse the
development of OA and achieve cartilage regeneration
(Bartha et al. 2006; Felson 2006).
Current efforts to develop regenerative medicine-based
therapeutic interventions for OA or focal cartilage defect
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repair include the use of autologous chondrocyte implantation
(ACI), often together with a polymer-based three-dimensional
scaffold matrix (Clouet et al. 2009; Getgood et al. 2009). In
ACI, arthroscopically isolated cartilage cells from an undam-
aged cartilage region are cultured in vitro to scale-up cell
numbers and seeded into scaffolds that are then implanted in
cartilage defects. In addition to autologous chondrocytes, oth-
er progenitor cells (i.e., bone marrow stromal cells, BMSCs
and umbilical cord stromal cells) have also been widely used
in such constructs (Clouet et al. 2009; Getgood et al. 2009;
Temenoff and Mikos 2000). Unfortunately, these tissue-
engineering (TE) approaches have not provided long-term
clinical benefit for patients suffering from OA or focal carti-
lage defects (Brittberg et al. 1994; Clouet et al. 2009; Getgood
et al. 2009; Lyngstadaas et al. 2009; Niemeyer et al. 2008;
Peterson et al. 2000; Temenoff and Mikos 2000). For exam-
ple, the occurrence of subsequent surgical procedures (SSPs)
is common following ACI (Phillip-Niemeyer et al. 2008), e.g.,
in one trial, 49 % of patients receiving ACI subsequently
underwent an SSP on the treated knee within 4 years of
initial treatment (Phillip-Niemeyer et al. 2008). Moreover,
symptomatic hypertrophy was observed following ACI
for patellar defects (Phillip-Niemeyer et al. 2008).
In view of the above, there would be great value in devel-
oping a therapy that could precondition and ‘prime’ autolo-
gous articular cartilage cells to produce hyaline cartilage-
associated ECM as well as suppress any aberrant hypertrophic
mineralization in ACI. We suggest that a novel molecule re-
lated to the enamel matrix derivative (EMD) may be useful in
this regard. EMD is a complex mixture of developmental pro-
teins (amelogenin and its proteolytic clipping forms/splicing
forms) and plays a pivotal role in craniofacial tissue develop-
ment (Lyngstadaas et al. 2009). We have recently shown that
EMD can modulate various differentiation pathways in
adult ligament precursor cells in vitro, including osteo-
genic, adipogenic and chondrogenic (Amin et al. 2012,
2013). We consider here tyrosine-rich amelogenin pep-
tide (TRAP), a 5.1-kDa isoform of EMD generated from
a full-length amelogenin through proteolytic clipping.
Both naturally occurring and chemically synthesized
forms of TRAP have recently been shown to suppress
bone-forming activity in various osteogenic precursor
cells (i.e., adult ligament cells and alveolar bone cells
(Amin et al. 2012)), although the effects of this peptide
on chondrogenic differentiation and hypertrophic miner-
alization have not hitherto been examined.
In view of TRAP’s ability to down-regulate osteogenic
differentiation (Amin et al. 2012), we hypothesized that TRAP
acts selectively on the mesenchymal lineage commitment
pathways. The present study therefore examines the effects
of chemically synthesized TRAP on chondrogenic differenti-
ation and hypertrophic mineralization of healthy human
chondrocytes in vitro.
Materials and methods
Cell culture
Ostensibly normal adult primary human articular cartilage
cells (HACs) from three male donors (ages 20–40 years; pur-
chased at passage 0 from Asterand, Roystone, UK) were used
in the present study. HACs were cultured in growth media
(GM) at 37 °C in a humidified atmosphere of 5 % CO2 in
air, as described previously (Amin et al. 2012, 2013, 2014).
Cells were scaled up in multilayer tissue culture flasks until
80–90% confluent, followed by experiments in pellet cultures
between passages 1 and 3. Detailed descriptions of the culture
media are given in the Supplementary material.
We chose to use HACs, rather than BMSCs, for the present
study determining the effects of TRAP on hypertrophic differ-
entiation for several reasons. First, bone marrow has a highly
heterogeneous stromal cell population, containing stem/
progenitor cells with the ability to undergo multi-lineage dif-
ferentiation, osteogenic progenitor cells and osteoblasts.
These osteogenic progenitor cells/osteoblasts can readily dif-
ferentiate and form bone-like mineralized nodules, confound-
ing the present study of hypertrophic mineralization, i.e., of
the endochondral ossification pathway where mature
chondrocytes undergo hypertrophy to form bone cells. Sec-
ond, the use of HACs better replicates the clinical scenario of
ACI, where cells harvested from existing cartilage are used.
Treatment of cells with TRAP
Chemically synthesized 45-amino acid TRAP (sequence:
NH2-MPLPPHPGHPGYINFSYEVLTPLKWYQNM
IRHPYTSYGYEPMGGW–COOH; purchased from Insight
Biotech, London, UK) was diluted in cell culture grade water
(Thermo Scientific, Basingstoke, UK) and added directly to
the culture media with cell pellets to yield a final concentration
of 1–100 μg/ml, previously shown to be within the solubility
limit for this form of TRAP (Amin et al. 2015).
Effects of TRAP on sGAG and ALP production of HACs
under chondrogenic conditions
Based on previous studies (Amin et al. 2012, 2013), we ex-
amined the effects of 1, 10, 50 and 100 μg/ml TRAP on
terminal chondrogenic differentiation of HACs cultured as
pellets, as described previously (Amin et al. 2014). Briefly,
cells were scaled up in GM, trypsinized and cultured
(0.5 × 106 cells/pellet in 15-ml conical polypropylene Falcon
tubes with caps loosened to allow gas exchange (Nunc)) in
GM overnight to obtain cell pellets. Culture media was then
replaced by fresh GM or chondrogenic media (CM), as de-
scribed previously (Amin et al. 2014). Cells cultured in non-
lineage-specific GM was used here as controls. Pellets were
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then cultured for 3 weeks in the presence or absence of TRAP.
After 3 weeks, chondrogenic differentiation was evaluated by
quantifying sulfated glycosaminoglycan (sGAG) content in
pellets (Blyscan kit; Biocolor, Carrickfergus, UK). ALP was
measured using a p-nitrophenyl phosphate kit (Sigma) in a
separate set of HAC pellets. Total DNA content was quanti-
fied using the PicoGreen® double-stranded DNA assay
(Invitrogen). All sGAG and ALP amounts were normalized
by DNA content. sGAG, ALP and DNA quantification assays
were carried out as per instructions from the manufacturers
and as previously described (Amin et al. 2012, 2014).
Effects of TRAP on sGAG and ALP production of HACs
under hypertrophic conditions
Cell pellets were first cultured in CM for 2 weeks
(Bpreconditioned^) in order to obtain functionally mature
chondrocytes (based on their ability to produce sGAG), as de-
scribed above. After 2 weeks of incubation with CM, these pel-
lets were further cultured in hypertrophic media (HTM) alone or
HTM+TRAP for 3 weeks, after which pellets underwent sGAG,
ALP andDNA quantification, as described above. Cells cultured
in non-lineage specific GM was used here as controls.
Methods for histology, immunocytochemistry and gene ex-
pression analyses are described in Supplementary materials.
Results
HACs (previously shown to contain a ‘stem’/progenitor cell-
like population (Williams et al. 2010)) were grown in pellet
culture and were exposed to a variety of conditions with or
without TRAP. Specifically, growth media (GM) was
employed to promote cell division, chondrogenic media
(CM) to promote chondrogenesis or hypertrophic media
(HTM) to promote hypertrophic mineralization.
In vitro functional outcomes: Effects of TRAP
on differentiation of articular cartilage cells
In TRAP-treated cells cultured in CM, a large dose-dependent
increase in sGAG levels was observed (Table 1); specifically,
10 and 50 μg/ml TRAP increased sGAG levels by 353 and
344 %, respectively, compared with control conditions of
HACs cultured in CM alone (p<0.05). Further, TRAP pro-
duced no significant change in alkaline phosphatase (ALP)
activity, a key functional indicator of terminal osteogenic dif-
ferentiation in vitro (Table 1). HACs cultured in GM in the
presence of TRAP (1–100 μg/ml) did not exhibit any change
in sGAG production or ALP activity (data not shown).
For determining the effects of TRAP on hypertrophic miner-
alization, HACswere first preconditioned for 2weeks in CMand
then cultured for 3 weeks in HTM or HTM+TRAP, as a simpli-
fied in vitro model of conditions changing from chondrogenic to
osteogenic in a process of endochondral ossification in osteoar-
thritic joints. Notably, cells cultured in the presence of TRAP
exhibited suppressed ALP activity (Table 1) compared to HACs
cultured without TRAP (p<0.05). Interestingly, this effect was
not dose-dependent, as 1–100 μg/ml TRAP concentrations
showed broadly similar effects.
Further, the results also showed that, at all concentrations
tested, TRAP-treated HACs cultured in HTM had sGAG
levels close to those of HACs grown in CM, while cell pellets
grown in HTM without TRAP had minimal sGAG levels
(p<0.05). Specifically, 10 and 50 μg/ml TRAP increased
sGAG levels by 418 and 325 %, respectively, compared with
cells grown without TRAP (p<0.05), with a maximal effect at
10 μg/ml TRAP (Table 1).
Table 1 Effects of various TRAP concentrations (1–100 μg/ml) on sGAG and ALP production by HACs
Growth media Chondrogenic media
0 μg/ml TRAP (control) 1 μg/ml TRAP 10 μg/ml TRAP 50 μg/ml TRAP 100 μg/ml TRAP
Relative sGAG/DNA (μg/μg) GM (3 weeks) CM (3 weeks)
1 3.6±1.1* 7.3±1.5*† 12.7±2.1*† 12.4±2.0*† 8.3±1.4*
GM (5 weeks) CM (2 weeks), followed by HTM (3 weeks)
1 1.6±1.1 3.4±1.2* 6.7±1.1*§ 5.2±1.2*§ 4.7±1.4*§
Relative ALP\DNA (μg/μg) GM (3 weeks) CM (3 weeks)
1 1.9±0.5* 1.9±0.5* 1.8±0.6 1.6±0.5 1.7±0.5
GM (5 weeks) CM (2 weeks), followed by HTM (3 weeks)
1 4.4±0.7* 1.4±0.2§ 1.6±0.4§ 0.9±0.1§ 0.9±2§
Row 2: sGAG levels assayed in cell pellets cultured in growth media (GM), chondrogenic media (CM) or CM+TRAP for 3 weeks. Row 4: sGAG levels
assayed in cell pellets preconditioned in CM for 2 weeks followed by 3 weeks of culture in hypertrophic media (HTM) or HTM+TRAP, for which
5 weeks of culture in GMwas used as a baseline. Rows 6 and 8: similar to rows 2 and 4, except that ALP levels are shown. The tabulated quantities are
the relative sGAG/DNA±SE and relative ALP/DNA±SE ratios, all normalized to values from cells with GM
†p<0.05 compared with CGM; *p<0.05 compared with CM alone; §p<0.05 compared with HTM alone
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Together, these data demonstrate that, when HACs are
grown under hypertrophic conditions, TRAP suppresses ter-
minal hypertrophic mineralization while maintaining sGAG
levels similar to those found in CM alone. Since 10 μg/ml
TRAP had the most pronounced effects, this concentration
was used for subsequent experiments.
In vitro terminal differentiation outcomes: Effects
of TRAP on HAC chondrogenic and osteogenic
differentiation
HAC pellets cultured for 3 weeks in CM with 10 μg/ml TRAP
showed strong Alcian blue staining (Fig. 1c), indicating abun-
dant ECM proteoglycans and glycosaminoglycans. In contrast,
control cultures grown in GM or CM without TRAP showed
weaker staining (Fig. 1a, b). A dark, purple-colored back-
ground staining of pellets grown in GM was also observed,
compared with the blue-coloredmatrix in CM and CM+TRAP.
The purple staining of pellets grown in GM may be due to the
residual non-specific background staining of Harris hematoxy-
lin. Additionally, strong Col2 staining in the ECM of HAC
pellets cultured in CM+TRAP was observed, compared with
relatively low levels of Col2 staining in cultures grown in CM
and little if any staining in cultures grown in GM (Fig. 1a’–c’).
Further, HAC pellets preconditioned in CM for 2 weeks
followed by 3 weeks of culture in HTM alone exhibited strong
Alizarin red staining of Ca+2-rich bone-like nodules; cells cul-
tured in GM showed little or no staining (Fig. 1b^). Notably,
10 μg/ml TRAP completely abolished staining for bone-like
nodules in HAC pellets cultured in HTM (Fig. 1c^). Further,
strong osteocalcin (OC) staining in the ECM of HAC pellets
was observed when cultured in HTM alone, while little or no
staining was observed for cells cultured in GM (Fig. 1a^’,
b^’). In contrast, TRAP completely abrogated OC staining
Fig. 1 Histology indicates that 10 μg/ml TRAP promotes chondrogenic
differentiation and suppresses hypertrophic mineralization. Labels on in-
dividual panels refer to culture media type: a–a^’ GM; b–b^’ CM; c–c^’
CM+TRAP. Note the intense bright blue staining of TRAP-treated cell
pellets stained with Alcian blue (c; indicative of glycosaminoglycans
present in the ECM) and the corresponding lack of Alizarin red staining
(c^; indicative of minimal calcium deposition). Note also the green fluo-
rescent staining of TRAP-treated cell pellets immuno-stained with Col2
(c’) and the corresponding lack of OC staining (c^’). Alcian blue and
Alizarin red sections were counter-stained with Harris Haematoxylin
(purple nuclei); Col2 and OC sections were counter-stained with Hoechst
dye (blue nuclei). Scale bar 100 μm
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in HAC pellets cultured in HTM (Fig. 1c^’). Thus, histology
confirms that TRAP suppresses terminal osteogenic differen-
tiation of HACs cultured under hypertrophic mineralization-
inducing conditions.
Gene expression analyses: Effects of TRAP on HAC
chondrogenic and osteogenic genes
Results showed that cells cultured in CM+10 μg/ml TRAP
had significantly higher levels of SOX9 (2.0-fold), ACAN (2.2-
fold) and COL2A1 (2.5-fold) transcripts, compared with cells
cultured in CM alone (p<0.05). As expected, HAC pellets
cultured in CM and in CM+TRAP expressed higher levels
of the early chondrogenic transcription factor SOX9 and the
late genes ACAN and COL2A1, compared with pellet cultures
in GM (p<0.05) (Fig. 2a), suggesting that TRAP induces both
early and late chondrogenic genes in HACs.
As expected, HAC pellets preconditioned in CM for
2 weeks followed by 1 week of culture in HTM alone
expressed higher levels of the early osteogenic/hypertrophic
marker Ihh and the late bone matrix gene BSP, compared with
pellet cultures in GM (Fig. 2b). However, cells cultured in
HTM+TRAP had significantly reduced transcript levels of
Ihh (59 % reduction; p<0.05) and BSP (55 % reduction;
p<0.05), compared with pellets cultured in HTM alone
(Fig. 2b). These results indicate that TRAP suppresses both
early and late pro-hypertrophic mineralization genes.
Discussion
Our results show that TRAP, a chemically synthesized
amelogenin protein isoform, suppresses hypertrophic mineraliza-
tion and concomitantly promotes chondrogenic differentiation of
HACs. This result is supported by data on expression levels of
both early and late pro-chondrogenic and pro-hypertrophic min-
eralization genes, as well as by data at the protein level. We note
that the above gene expression study was carried out using a
conventional semi-quantitative RT-PCR; use of a quantitative
gene expression assay technique (quantitative-real-time PCR)
would be beneficial for future studies.
SOX9 up-regulation is a pivotal upstream chondrogenic
event in the up-regulation of COL2A1, ACAN and in sGAG
production (Bi et al. 1999), while RUNX2 up-regulation is a
key upstream osteogenic event in the up-regulation of OC, BSP
and in ALP production (Kim et al. 2013). In view of our pre-
vious report showing that TRAP suppresses bone-forming ac-
tivity through Smad6-mediated RUNX2 inhibition (Amin et al.
2012), it is possible that TRAP may be differentially regulating
chondrogenic and osteogenic activity of adult precursor cells by
regulating activities of the ‘key’ lineage-specific early transcrip-
tion factors SOX9 and RUNX2 (Bi et al. 1999; Kim et al. 2013).
This hypothesis requires further investigation.
The pro-chondrogenic effects of 10 μg/ml TRAP were ob-
served when cells were cultured in full chondrogenic condi-
tions (an environment facilitating chondrogenesis) but not in
non-selective growth conditions. This suggests that an envi-
ronment favoring chondrogenesis, e.g., one in which TGF-β3
is present, may be essential for TRAP-mediated chondrogen-
esis. In future studies, it might therefore be important to iden-
tify molecular mechanisms involved in TRAP-induced chon-
drogenesis in order to understand this synergy between TRAP
and chondrogenic media components.
As noted above, TRAP is a proteolytic product of full-length
amelogenin and is shown to be secreted as part of a heteroge-
neous mixture of EMP during craniofacial developmental
(Lyngstadaas et al. 2009). In the natural form of TRAP, the
SER16 amino acid has been shown to be phosphorylated
(Lyngstadaas et al. 2009). Although the present study did not
examine the effects of phospho-SER16 TRAP on osteogenic
and chondrogenic differentiation, we have shown in our previ-
ous studies that both naturally occurring phospho-SER16
Fig. 2 Ten μg/ml TRAP enhances mRNA levels of pro-chondrogenic
genes and suppresses levels of hypertrophic mineralization genes. a Note
the up-regulation of the early chondrogenic gene SOX9 and the late genes
ACAN andCOL2A1 of HAC pellets treated with TRAP. bNote the down-
regulation of the early hypertrophic mineralization gene Ihh and the late
bone gene BSP of TRAP-treated HAC pellets. Plotted values are the
means±SE of triplicate measurements, as described in the text.
*p<0.05 compared with GM; *†p<0.05 compared with CM alone; or
*§p<0.05 compared with HTM alone
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TRAP and chemically synthesized non-phosphorylated TRAP
exhibited the same inhibitory effects on osteogenic differentia-
tion (Amin et al. 2012). Thus, the present study focused on
examining the effects of the non-phosphorylated synthetic form
of TRAP on osteogenic and chondrogenic differentiation of
chondrocytes. TE strategies for cartilage replacement, based
on autologous chondrocytes and MSCs, have recently received
significant attention (Amin et al. 2014; Getgood et al. 2009).
However, any long-term cartilage repair strategy based on ACI
must incorporate methods to prime autologous chondrocytes
for cartilage-specific matrix production while suppressing the
hypertrophic mineralization pathway, so as to prevent
athrofibrosis, joint adhesion, cartilage injury and symptomatic
hypertrophy post-ACI (Brittberg et al. 1994; Dreier 2010;
Goldring and Goldring 2010; Niemeyer et al. 2008; Peterson
et al. 2000). Although we recognize that this is a cell culture-
based study, with the limitations implied thereby, our results
motivate further investigation into the use of TRAP for the
above purpose. Specifically, future experiments/investigations
should examine three specific points: (1) determine the molec-
ular mechanism(s) involved in TRAP-mediated chondrogenic
differentiation and suppression of hypertrophic bone formation;
(2) identify and characterize an articular cartilage cellular subset
(if present) that specifically reacts to the TRAP signal(s); and
(3) ultra-structurally compare TRAP-stimulated cartilage to
pristine cartilage and fibrocartilage.
If further studies with TRAP are promising, there may be a
number of advantages to the eventual clinical use of TRAP:
(1) due to its small size (45 amino acids), the chemically
synthesized peptide should be relatively inexpensive to pro-
duce in substantial quantities with high purity; (2) TRAP can
potentially increase the effectiveness of ACI procedures, both
for OA patients and for patients with focal cartilage defects
due to sports (or other) injuries; and (3) incorporation of a cell
preconditioning step into a well-established, routine ACI pro-
tocol would be relatively easy. We hope that this approach can
eventually delay/reduce the need for expensive surgical pro-
cedures involving prosthetic implants and increase the quality
of life for patients suffering from joint defects.
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